Skip to main content

Table 3 Uni- and multivariate analyses of factors associated with 3-year overall survival (OS) and recurrence-free survival (RFS) rates in g-NENs patients

From: Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series

Variable

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

3-year OS

3-year OS

3-year RFS

3-year RFS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Gender

 Male

1

   

1

   

 Female

0.650 (0.338–1.248)

0.195

  

0.813 (0.419–1.580)

0.542

  

Age (years)

 < 65

1

   

1

   

 ≥ 65

1.112 (0.669–1.847)

0.683

  

0.851 (0.488–1.483)

0.569

  

BMI(kg/m2)

 < 25

1

   

1

   

 ≥ 25

0.694 (0.330–1.460)

0.336

  

0.709 (0.320–1.570)

0.396

  

ASA

 1

1

 

1

 

1

 

1

 

 2

1.934 (1.118–3.347)

0.018

1.869 (1.069–3.269)

0.028

2.118 (1.196–3.749)

0.010

2.191 (1.223–3.924)

0.008

 3

2.54 (1.172–5.504)

0.018

2.029 (0.917–4.486)

0.081

1.294 (0.487–3.437)

0.605

0.875 (0.324–2.361)

0.791

Comorbidity

 No

1

   

1

   

 Yes

1.346 (0.751–2.411)

0.318

  

0.993 (0.552–1.785)

0.981

  

Tumor (mm)

 < 50

1

   

1

   

 ≥ 50

1.596 (0.957–2.659)

0.073

  

1.449 (0.841–2.496)

0.181

  

Tumor location

 Upper

1

   

1

   

 Middle

0.664 (0.314–1.403)

0.283

  

0.778 (0.349–1.734)

0.540

  

 Lower

0.917 (0.484–1.735)

0.789

  

1.104 (0.571–2.135)

0.769

  

 Mix

1.253 (0.593–2.649)

0.555

  

1.147 (0.494–2.664)

0.749

  

T stage

 T1 + T2

1

 

1

 

1

   

 T3 + T4

1.748 (1.054–2.898)

0.031

1.445 (0.843–2.476)

0.181

1.568 (0.914–2.691)

0.103

  

N stage

 N0

1

 

1

 

1

 

1

 

 N1

5.032 (2.385–10.616)

<.001

3.554 (1.624–7.778)

0.002

5.882 (2.507–13.804)

<.001

4.710 (1.966–11.283)

0.001

Surgical method

 Open

1

   

1

   

 Laparoscopic

0.797 (0.472–1.344)

0.395

  

0.875 (0.496–1.546)

0.647

  

Gastrectomy extent

 Total

1

   

1

   

 Distal

0.74 (0.400–1.368)

0.337

  

1.080 (0.584–1.994)

0.807

  

 Proximal

0.418 (0.058–3.029)

0.388

  

0.528 (0.072–3.850)

0.529

  

Pathological type

 NET

1

   

1

   

 NEC

2.352 (0.712–7.773)

0.161

  

1.521 (0.524–4.414)

0.441

  

 MANEC

1.839 (0.563–6.008)

0.313

  

1.172 (0.410–3.350)

0.767

  

Ki-67 positive index (%)

 < 60

1

 

1

 

1

 

1

 

 ≥ 60

4.753 (2.469–9.152)

<.001

3.492 (1.772–6.879)

<.001

5.978 (2.810–12.718)

<.001

4.304 (1.981–9.350)

<.001

Complication

 No

1

   

1

   

 Yes

1.645 (0.994–2.723)

0.053

  

1.245 (0.699–2.220)

0.457

  

Adjuvant chemotherapy

 No

1

   

1

   

 Yes

1.409 (0.843–2.355)

0.191

  

1.559 (0.894–2.719)

0.117

  

Martin et al. [27]

 High

1

   

1

   

 Low

1.181 (0.709–1.968)

0.523

  

1.377 (0.790–2.400)

0.260

  

 SMI

        

 High

1

 

1

 

1

 

1

 

 Low

2.061 (1.243–3.420)

0.005

2.098 (1.239–3.553)

0.006

1.758 (1.025–3.018)

0.041

1.780 (1.029–3.076)

0.039

  1. g-NENs gastric neuroendocrine neoplasms, HR Hazard ratio, CI Confidence interval, BMI Body mass index, ASA American Society of Anesthesiologists, NET Neuroendocrine tumor, NEC Neuroendocrine carcinoma, MANEC Mixed adenoneuroendocrine carcinoma, SMI Skeletal muscle index